Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986393 + mezigdomide
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
BMS-986393 + mezigdomide is an investigational drug combination being studied in relapsed and/or refractory multiple myeloma. BMS-986393 (arlocabtagene autoleucel, also known as CC-95266) is an autologous chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D, a protein expressed on malignant plasma cells. Mezigdomide (CC-92480) is a novel cereblon E3 ligase modulator (CELMoD) and protein degrader; it acts by stimulating the immune system and targeting degradation of tumor-promoting proteins, promoting direct cytotoxicity to multiple myeloma cells. This combination aims to improve anti-myeloma activity by simultaneously employing cell therapy and protein degradation mechanisms. Both drugs are being developed and studied in combination for patients with multiple myeloma who have failed previous standard therapies[1][3][4][5][9].
- Other names
- arlocabtagene autoleucel + mezigdomide
02
Targets
IKZF3 (Zinc finger protein Aiolos)CRBN (Cereblon)GPRC5DIKZF1 (Ikaros family zinc finger protein 1)
Beyond the preview
Go deeper on BMS-986393 + mezigdomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986393 + mezigdomide.